Abstract
AbstractWe used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent Original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection was higher after prior Omicron infection than after bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalizations, we found limited added benefit in preventing SARS-CoV-2 infection.
Publisher
Cold Spring Harbor Laboratory
Reference11 articles.
1. World Health Organization. One year since the emergence of COVID-19 virus variant Omicron 2022 [18 January 2022]. Available from: https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-omicron.
2. Huiberts A , Kooijman M , Melker H , Hahne S , Grobbee D , Hoeve C , et al. Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO) [PREPRINT]. Research Square. 2022.
3. Huiberts AJ , de Gier B , Hoeve CE , de Melker HE , Hahné SJM , Hartog Gd , et al. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study [PREPRINT]. medRxiv. 2023:2023.01.09.23284335.
4. Rijksoverheid. Coronadashboard: Virusdeeltjes in rioolwater 2022 [17 January 2023]. Available from: https://coronadashboard.government.nl/landelijk/rioolwater.
5. Rijksoverheid. Coronadashboard: Positief geteste mensen 2022 [17 January 2023]. Available from: https://coronadashboard.rijksoverheid.nl/landelijk/positief-geteste-mensen.